AUP:CA:TSX-Aurinia Pharmaceuticals Inc (CAD)

COMMON STOCK | Technical & System Software | TSX

Last Closing Price

CAD 16.76

Change

0.00 (0.00)%

Market Cap

CAD 2.15B

Volume

4.61M

Avg Analyst Target

CAD 32.50 (+93.91%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aurinia Pharmaceuticals Inc (AUP) Stock Analysis:
Based on the Aurinia Pharmaceuticals Inc stock forecasts from 1 analysts, the average analyst target price for Aurinia Pharmaceuticals Inc is CAD 32.50 over the next 12 months. Aurinia Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aurinia Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Aurinia Pharmaceuticals Inc’s stock price was CAD 16.76. Aurinia Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -24.84% over the last year.

About

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaborati ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Technical & System Software

ETFs Containing AUP:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Technical & System Software)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -24.84% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.84% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 323.23% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 323.23% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.98% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.98% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 77.33% N/A N/A N/A N/A
Risk Adjusted Return 50.40% N/A N/A N/A N/A
Market Capitalization 2.15B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Technical & System Software)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.67 N/A N/A N/A N/A
Price / Cash Flow Ratio -30.75 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -51.67% N/A N/A N/A N/A
Return on Invested Capital -28.59% N/A N/A N/A N/A
Return on Assets -27.15% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.99 N/A N/A N/A N/A
Short Percent 0.92% N/A N/A N/A N/A
Beta 0.28 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.